naselin/nasivision/nasoclear or ryaltriz az nasal drops
Reading File
Finding Sources
Finding Sources
Searching the Web
Naselin Nasivion Nasoclear Ryaltriz AZ nasal drops composition comparison India
Searching the Web
Ryaltriz AZ nasal spray composition olopatadine mometasone Glenmark India
Searching the Web
Naselin nasal drops composition xylometazoline India brand
Finding Sources
Searching the Web
Nasoclear nasal drops composition sodium chloride saline India brand
Finding Sources
I now have all the information needed for a thorough comparison. Here is a complete breakdown:
Naselin / Nasivion / Nasoclear / Ryaltris-AZ - Nasal Drops Comparison
These four products belong to completely different pharmacological categories. Here is a detailed comparison:
1. NASELIN (Cipla Health)
| Parameter | Details |
|---|---|
| Active ingredient | Oxymetazoline Hydrochloride 0.05% w/v |
| Class | Alpha-adrenergic agonist (sympathomimetic) - topical nasal decongestant |
| Mechanism | Directly stimulates α1 and α2 receptors on nasal blood vessels → vasoconstriction → reduces mucosal congestion |
| Indication | Nasal congestion due to common cold, sinusitis, allergic rhinitis (short-term relief) |
| Dose | 2-3 drops in each nostril, 2-3 times daily; max 5-7 days |
| Onset | Rapid (within minutes) |
| Duration | 10-12 hours (long-acting among imidazolines) |
| Preservative | Benzalkonium chloride |
| MRP | ~₹72 / 10 mL |
| Key caution | Do NOT use >7 days - causes rhinitis medicamentosa (rebound congestion) |
2. NASIVION (P&G / Merck)
Available in three concentrations for different age groups:
| Product | Oxymetazoline Conc. | Age Group | Dose |
|---|---|---|---|
| Nasivion Mini (Baby Drops) | 0.01% (0.01 mg/mL) | < 1 year (babies) | 1-2 drops/nostril, 2-3×/day |
| Nasivion Paediatric | 0.025% | 1-6 years | 1-2 drops/nostril, 2-3×/day |
| Nasivion Adult | 0.05% | > 6 years/adults | 2-3 drops/nostril, 2-3×/day |
- Class: Same as Naselin - Oxymetazoline-based topical nasal decongestant
- Preservative: Benzalkonium Chloride 50% IP (0.3 mg/mL)
- Key distinction: Age-stratified concentrations make it safer than using adult-strength drops in infants
- Onset: ~25 seconds per clinical study data (adult 0.05% formulation)
- Same caution: Not to be used >7 consecutive days
Naselin vs Nasivion: Pharmacologically identical (both oxymetazoline 0.05% for adults). Nasivion's main advantage is the availability of 0.01% and 0.025% formulations for infants and children.
3. NASOCLEAR (Saline Nasal Drops)
| Parameter | Details |
|---|---|
| Active ingredient | Sodium Chloride 0.65% w/v (isotonic/slightly hypotonic saline) |
| Class | Saline nasal wash - non-pharmacological/mechanical agent |
| Mechanism | Humidifies dry nasal passages, loosens thick secretions, facilitates mucociliary clearance, washes out allergens and irritants |
| Preservative | Benzalkonium Chloride 0.01% w/v |
| Indication | Nasal dryness, thick secretions, mild congestion in cold/allergies; adjunct therapy; safe for infants |
| Dose | 2-3 drops in each nostril as needed - can be used freely throughout the day |
| Onset | Immediate (mechanical effect) |
| Age | Suitable for all ages including neonates |
| Key benefit | No rebound congestion, no systemic side effects, can be used long-term |
| MRP | ~₹73 / 20 mL |
Nasoclear is fundamentally different from Naselin/Nasivion - it is a saline rinse, not a decongestant.
4. RYALTRIS-AZ Nasal Spray (Glenmark Pharmaceuticals)
| Parameter | Details |
|---|---|
| Active ingredients | Mometasone Furoate 50 mcg + Azelastine HCl 140 mcg per actuation |
| Class | Fixed-dose combination: Intranasal corticosteroid (INCS) + H1 antihistamine |
| Mechanism | Mometasone → reduces nasal mucosal inflammation via glucocorticoid receptors; Azelastine → blocks H1 histamine receptors + has anti-inflammatory properties |
| Indication | Moderate-to-severe allergic rhinitis (seasonal & perennial), including both nasal and ocular symptoms; patients ≥12 years |
| Dose | 1-2 sprays per nostril twice daily |
| Onset | Symptom relief can begin within 15-60 minutes (azelastine component); full steroid effect takes days-weeks |
| Covers | Sneezing, rhinorrhoea, nasal itching, nasal congestion, itchy/watery/red eyes |
| Key note | First company worldwide to launch this Mometasone + Azelastine FDC (launched India, May 2021). Different from the global RYALTRIS (which uses Mometasone + Olopatadine). |
| Requires prescription | Yes |
| Not for | Simple cold/viral nasal congestion; not for children <12 years |
Important distinction: The global RYALTRIS (US/EU/Australia) uses Mometasone + Olopatadine, while RYALTRIS-AZ (India, Glenmark) uses Mometasone + Azelastine - these are different products sharing a similar brand name.
Summary Comparison Table
| Feature | Naselin | Nasivion | Nasoclear | Ryaltris-AZ |
|---|---|---|---|---|
| Drug | Oxymetazoline 0.05% | Oxymetazoline 0.01-0.05% | NaCl 0.65% | Mometasone 50mcg + Azelastine 140mcg |
| Class | Decongestant | Decongestant | Saline wash | Steroid + Antihistamine |
| Indication | Congestion (short-term) | Congestion (age-stratified) | Dryness/secretions | Allergic rhinitis (moderate-severe) |
| Onset | Minutes | Seconds (25s claimed) | Immediate | 15 min (antihistamine); days (steroid) |
| Duration of use | Max 7 days | Max 7 days | Unlimited | Long-term (for AR) |
| Prescription | OTC | OTC | OTC | Rx |
| Age | Adults | All ages (different strengths) | All ages | ≥12 years |
| Side effects | Rebound congestion (>7d), stinging | Same as Naselin | Minimal | Dysgeusia, epistaxis, nasal irritation |
Clinical Guidance on When to Use Which
- Viral cold with blocked nose (acute): Naselin or Nasivion (for quick relief, ≤5 days)
- Infant/child nasal congestion: Nasivion Mini (0.01%) or Nasoclear
- Dry nose / thick secretions / adjunct therapy: Nasoclear
- Moderate-severe allergic rhinitis (hay fever, perennial AR): Ryaltris-AZ - addresses both sneezing/itch (azelastine) and inflammation/congestion (mometasone)
- Never use Naselin/Nasivion >7 days - causes rhinitis medicamentosa (rebound congestion from interstitial edema when vasoconstriction wears off), as confirmed in Scott-Brown's Otorhinolaryngology and multiple family medicine textbooks.
This is a shared conversation. Sign in to Orris to start your own chat.